Syndax Pharmaceuticals, Inc.
SNDX
$16.24
$0.402.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 717.14% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 984.51% | -- | -- | -- | -- |
| Cost of Revenue | 30.52% | -- | 20.37% | 81.57% | 39.96% |
| Gross Profit | 43.42% | -- | -6.44% | -49.59% | -29.89% |
| SG&A Expenses | 50.73% | 78.23% | 65.46% | 80.14% | 94.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.08% | 30.23% | 33.55% | 81.13% | 56.44% |
| Operating Income | 6.55% | -5.03% | -23.70% | -58.95% | -49.39% |
| Income Before Tax | -5.56% | -17.19% | -29.94% | -64.48% | -52.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.56% | -17.19% | -29.94% | -64.48% | -52.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.56% | -17.19% | -29.94% | -64.48% | -52.56% |
| EBIT | 6.55% | -5.03% | -23.70% | -58.95% | -49.39% |
| EBITDA | 6.55% | -5.03% | -23.70% | -58.96% | -49.40% |
| EPS Basic | -4.26% | -15.89% | -9.85% | -34.49% | -24.58% |
| Normalized Basic EPS | -4.25% | -15.89% | -9.83% | -34.48% | -24.60% |
| EPS Diluted | -4.03% | -15.84% | -9.32% | -34.49% | -24.86% |
| Normalized Diluted EPS | -4.25% | -15.89% | -9.83% | -34.48% | -24.60% |
| Average Basic Shares Outstanding | 1.25% | 1.13% | 18.30% | 22.30% | 22.45% |
| Average Diluted Shares Outstanding | 1.25% | 1.13% | 18.30% | 22.30% | 22.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |